Zoetis Inc. $ZTS Shares Acquired by Intech Investment Management LLC

29 May 2026, 07:48 by Doug Wharley · The Cerbat Gem

Intech Investment Management LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 154.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 464,141 shares of the company’s stock after buying an additional 281,566 shares during the period. Zoetis accounts for 0.5% of Intech Investment Management LLC’s portfolio, making the stock its 23rd biggest position. Intech Investment Management LLC’s holdings in Zoetis were worth $58,398,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust acquired a new position in shares of Zoetis during the fourth quarter worth $4,661,000. Geode Capital Management LLC increased its position in shares of Zoetis by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after acquiring an additional 189,235 shares during the period. Malaga Cove Capital LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $280,000. Smithfield Trust Co increased its position in shares of Zoetis by 4.2% in the 4th quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after acquiring an additional 92 shares during the period. Finally, AR Asset Management Inc. increased its position in shares of Zoetis by 11.8% in the 4th quarter. AR Asset Management Inc. now owns 37,864 shares of the company’s stock valued at $4,764,000 after acquiring an additional 4,000 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may help reassure investors by giving management a venue to discuss strategy, operations, and the path forward. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Neutral Sentiment: Argus reiterated a “hold” rating on Zoetis, suggesting analysts are not currently seeing a major catalyst for a near-term rebound. Zoetis had its “hold” rating reaffirmed by Argus
Negative Sentiment: Multiple law firms announced or expanded class action efforts against Zoetis, with investors alleging harm tied to the period from January 14, 2025 through May 6, 2026; these repeated filings keep legal overhang front and center for shareholders. Rosen Law Firm Urges Zoetis Inc. (NYSE: ZTS) Stockholders to Contact the Firm for Information About Their Rights
Negative Sentiment: The lawsuits stem from Zoetis’ Q1 results, when the company missed earnings and revenue estimates and cut full-year guidance, raising concerns about growth and execution. Zoetis (ZTS) Securities Fraud Investigation – Levi & Korsinsky

Analysts Set New Price Targets

Several equities analysts recently issued reports on ZTS shares. UBS Group cut their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Bank of America upped their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $133.92.

Get Our Latest Report on Zoetis

Zoetis Trading Down 1.4%

NYSE ZTS opened at $78.36 on Friday. The company has a fifty day moving average of $105.08 and a 200 day moving average of $117.31. The company has a market capitalization of $32.85 billion, a PE ratio of 12.99, a P/E/G ratio of 1.30 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $172.23.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts forecast that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Insiders Place Their Bets

In related news, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

About Zoetis

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).